Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 801–900 of 1,000
Novel sGC stimulator improves outcomes in patients with HFrEF
Huynh, K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0382-z · Cited by 3
Medication Burden in Older Patients With Heart Failure: A Cohort Study of Medicare Beneficiaries
Umarje, S. P., Vaduganathan, M., Levin, R., & Desai, R. J. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.022 · Cited by 3
Yoshino, K., Takahashi, K., Eda, Y., Nishigaki, A., & Kitao, M. (1991) · PubMed · Cited by 4
Blanton, R. M. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007107 · Cited by 3
Vericiguat in Heart Failure With Reduced Ejection Fraction With High Natriuretic Peptides
Cunningham, J. W., & Jhund, P. S. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.09.001 · Cited by 3
Stand [Up] and Stand by for New Strategies for Treating Acute Heart Failure
Greenberg, B., & Urey, M. A. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.11.001 · Cited by 3
Warren, P. F. (2009) · ProQuest LLC eBooks · Cited by 4
Emdin, M., Aimo, A., & Castiglione, V. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2511 · Cited by 3
Praliciguat and Soluble Guanylate Cyclase Stimulators for Peripheral Artery Disease
Kosmac, K., Ismaeel, A., Kim‐Shapiro, D. B., & McDermott, M. M. (2023) · Circulation Research · doi:10.1161/circresaha.122.322298 · Cited by 3
Kittleson, M. M. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.019 · Cited by 3
Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment
Wang, C., Fu, G., Wang, X., & Li, N. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2506230 · Cited by 4
“Rates of CVD or HF hospitalization were lower with veri-ciguat than with placebo (HR: 0.90, 95% CI: 0.83–0.98, p = 0.02) [73].”
BackgroundInfluentialRodríguez‐Zavala, J. S., & Zazueta, C. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400492 · Cited by 2
Taha, H., Momtaz, M., Elamragy, A. A., Younis, O., & Fahim, M. A. S. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10453-3 · Cited by 3
“The study was hailed for allowing a lower limit of baseline eGFR of 15 mL/min/1.73 m 2 [92], which meant that HFrEF patients with advanced stage 4 CKD could benefit from the medication.”
InfluentialBotero, S. N. R., Martínez, M. R., Fácila, L., Álvarez, A. L., Balaguer, V. M., Escrivá, D. G., Chover‐Sierra, E., Montagud, Á. S., & Pérez-Silvestre, J. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2024.11.005 · Cited by 2
Azab, N. F. E., Mustafa, D. M., & Magdy, N. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113782 · Cited by 2
Seth, S., Chopra, V., Mantri, R. R., Modi, S., Mittal, S., Balagopalan, J. P., Aggarwal, V., Mehrotra, R., Mishra, S., Vivek, B. S., et al. (2025) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_23_25 · Cited by 2
Lu, M., Wang, B., Rong, C., Wang, Y., & Zhang, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1579112 · Cited by 4
Lisi, D. L., Gaddis, K., & Abdou, M. H. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.003 · Cited by 2
Yan, B., Zhang, J., Wang, J., & Yuan, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1501330 · Cited by 3
Xu, B., Yuan, Y. Y., Gao, L., Wang, Z., Lv, Z., Yu, W. C., Jin, H., Zhen, Z., Zhao, Z., Na, J., et al. (2025) · Children · doi:10.3390/children12070880 · Cited by 4
“…sodium–glucose cotransporter 2 (SGLT2) inhibitors empagliflozin [17] and dapagliflozin [18]; the soluble guanylate cyclase stimulator vilexiguat [19]; the specific cardiac myosin activator omecamtiv mecarbil [20], etc. Notably, analogous large-scale studies have not yet been reported in the…”
Ponde, C. K., MOHAN, J. C., Oomman, A., Kumar, D., HAZRA, P. K., & Jadhav, D. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.001 · Cited by 2
Mapelli, M., Mattavelli, I., Salvioni, E., Banfi, C., Mallia, A., Galotta, A., Mantegazza, V., Garlaschè, A., Campodonico, J., Rubbo, F. M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167696 · Cited by 4
Fudim, M., YARANOV, D. M., Gupta, R., Letarte, L., Sears, S. F., Howard, B. G., Uriel, N. Y., Raje, V., Mahmood, K., Pinney, S., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.08.019 · Cited by 2
Tissue-specific regulation of NO-GC isoforms in the cardiovascular system
Giesen, J., Menges, L., & Benndorf, R. A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117384 · Cited by 3
D’Elia, S., Gentile, C., Solimene, A., Franzese, R., Luisi, E., Caiazzo, A., Marotta, L., Covino, S., Natale, F., Loffredo, F. S., et al. (2025) · Biomolecules · doi:10.3390/biom15101420 · Cited by 7
“The main adverse events were symptomatic hypotension, syncope, and anemia [80].”
Kinoshita, H., Sugino, H., Kodama, M., Saito, M., Sumimoto, Y., Masada, K., Shimonaga, T., Suga, A., Toko, M., Taniyasu, K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70059 · Cited by 2
Zhou, B.-Y., Zhang, C.-Y., Zhang, Y., Ren, N., & Geng, J. (2025) · Cardiology · doi:10.1159/000549270 · Cited by 2
Advances in the management of acute decompensated heart failure
Gottlieb, M. A., Bellolio, F., Long, B., & Storrow, A. B. (2025) · BMJ · doi:10.1136/bmj-2025-084242 · Cited by 8
Update on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
“…with recent WHF despite optimized therapy, vericiguat significantly reduced the composite endpoint of cardiovascular death or HF hospitalization compared with placebo, with the greatest benefit observed in patients with moderately elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) [8].”
Revisiting soluble guanylate cyclase pharmacology: Additive potential of stimulators and activators
Petraina, A., Elbatreek, M. H., Neullens, C. T., Saridaki, T., Dao, V. T.-V., Szepanowski, F., Martin, E., Sippl, W., Casas, A. I., & Schmidt, H. H. H. W. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118762 · Cited by 2
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
“2), novel candidates (endothelin-1 antagonists [116, 117], soluble guanylyl cyclase [118], and aldosterone synthesis inhibitors [119]) require validation in large diverse cohorts with dual cardiorenal endpoints.”
Ma, Y., Xu, L., Lin, Y., Zhu, J., Liu, J., Wang, L., & Chen, L. (2025) · Kidney Diseases · doi:10.1159/000548430 · Cited by 2
Li, Y., Hu, B., Xiao, P., Han, L., Tong, Z., Xu, J. M., Jiao, Y.-Q., Song, M., Wang, Z., Zhang, W., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117570 · Cited by 2
ELAD, B., Lotan, D., Richter, I., Changhee, L., Raikhelkar, J., Clerkin, K. J., Fried, J., SAYER, G. T., & Uriel, N. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001761 · Cited by 2
Bajec, T., Žorž, N., Ugovšek, S., Zemljič, G., Cerar, A., Frljak, S., Okrajšek, R., Sušanj, P. G., Šebeštjen, M., Vrtovec, B., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13010017 · Cited by 3
“…with greater reductions in NT-proBNP levels [14], and the phase 3 VICTORIA trial later demonstrated that vericiguat significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients with HFrEF and recent decompensation (35.5% vs. 38.5%, p = 0.02) [15].”
InfluentialLiu, X., Tang, M., Lu, J., Kong, Y., Shen, W., Zhang, C., & Yang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1756582 · Cited by 3
Wang, M., Zuo, Z., Wu, T., & Zhou, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1644757 · Cited by 3
Castelletti, F., BIANCO, E., Fabro, G., Nicolini, E., Dentali, F., Liberale, L., Tangianu, F., & Bonaventura, A. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70173 · Cited by 2
“Although an initial analysis suggested that patients aged ≥ 75 years may not derive benefit from vericiguat, 10 a subsequent detailed investigation showed that while older patients – particularly men – had higher baseline risk for the primary composite outcome and its components, the efficacy of…”
Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study
Chen, J., Liu, J., Xiao, R., Wang, Y., Gao, L., Zhao, W., Li, Z., He, S., Zhang, Y., Wen, X., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046168 · Cited by 2
“…other GDMTs. 10 This consistency in safety is corroborated by the VICTORIA trial, where vericiguat showed no significant difference in symptomatic hypotension compared with placebo, 13 and no increased risk of hyperkalemia or acute kidney injury was found across different levels of renal function.”
Jin, L., & Yang, T. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70150 · Cited by 2
Mallardo, M., Filardi, P. P., Micheletto, C., Montano, N., Spampinato, A., Volterrani, M., Zito, G., Agosti, S., Avogadri, E., Basile, C., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106881 · Cited by 2
Cost-Effectiveness of Therapies for Heart Failure in Brazil: A Systematic Review
Pereira, G. A. R., Lopes, M. D. C., Dama, B. L., Polanczyk, C. A., & Bertoldi, E. G. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250712i · Cited by 2
“31 A subsequent economic analysis estimated an ICER of US$ 124,512/QALY, classifying it as an intermediate-value therapy in the US population.”
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches
Dunlay, S. M., Colvin, M. M., Cowger, J. A., Leiro, M. G. C., Desai, A. S., Greene, S. J., Gustafsson, F., HALL, S., Ilonze, O. J., Lala, A., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103101 · Cited by 3
Self-citationMeekers, E. M., Martens, P., Dauw, J., Dhont, S., Verbrugge, F. H., Nijst, P., Tartaglia, K., Chenot, F., Moubayed, S., Dierckx, R., et al. (2026) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2026.2704235 · Cited by 2
“Despite implementation of disease-modifying agents, hospital-isation rates have been reported to exceed 20% within 1 year in ambulatory patients with heart failure [1–3].”
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Wells, Q. S., Farber‐Eger, E. H., Lipworth, L., Dluzniewski, P., Dent, R., Umeijiego, J., & Cohen, S. S. (2022) · Clinical Epidemiology · doi:10.2147/clep.s341919 · Cited by 2
“Although this analysis was conducted in a single quaternary care hospital with a high-volume HF and transplantation program geographically located in a region with a high burden of HF, the findings, including demographic and clinical characteristics, are largely in agreement with published baseline data from GALACTIC-…”
ResultGarner, D., Lunt, L., Leung, W. Y., Llewellyn, J., Kahn, M., Wright, D. J., & Rao, A. (2022) · Sensors · doi:10.3390/s22051825 · Cited by 2
“Background medical therapy was comparable to other contemporary studies with 85% of patients on ACEi/ARB/ARNI modifiers (the remainder intolerant of them), 93% on BB and 63% on MRA, reflecting optimised HF management [22].”
ResultA multidisciplinary approach to heart failure care in the hospital: improving the patient journey
Rao, V. U., Bhasin, A., Vargas, J., & Kumar, V. A. (2022) · Hospital Practice · doi:10.1080/21548331.2022.2082776 · Cited by 3
Piña, I. L., Gibson, G. T., Zieroth, S. R., & Kataria, R. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac112 · Cited by 3
“Vericiguat is now approved as an adjunct to Guideline Directed Medical Therapy (GDMT) following the positive randomized controlled Study of Vericiguat in Participants with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial, which had one of the highest event rates out of recent trials, but with no significa…”
MethodHu, T., Liu, Y., & Lou, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.925375 · Cited by 3
“In addition to sacubitril–valsartan, vericiguat and sodiumdependent glucose transporters 2 inhibitors (SGLT2i) have also been proven effective in ADHF or acute HF treatment (Armstrong et al., 2020; Bhatt et al., 2021).”
BackgroundSchoenborn, E. M., Skersick, P., THRASHER, C., & nd, R. L. P. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2839 · Cited by 2
“For example, the primary outcome in DELIVER added urgent HF visits to CV death or HF hospitalizations, (2) the EMPERORPreserved trial did not require documentation of physical findings or laboratory tests for confirming an HF hospitalization and it included events of 12– 24 h if intensification of treatment was not on…”
BackgroundPalomas, J. L. B., de Polavieja, J. I. M. G., Pérez, M. P., Rangel‐Sousa, D., Fernández, A. C., Aguilera, J. L., Cortés, C. O., & Calvo, F. T. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2215985 · Cited by 2
“By contrast, the recent VICTORIA trial included patients hospitalized with HF within the first 3–6 months before randomization or requiring intravenous diuretic therapy without being hospitalized during the previous 3 months [31] and the SOLOIST-WHF study included patients with type 2”
BackgroundMethodBallantyne, B. A., Vandenberk, B., Dykstra, S., Labib, D., Chew, D. S., Lydell, C. P., Howarth, A. G., Heydari, B., Fine, N. M., Howlett, J. G., et al. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02904-z · Cited by 2
Cardiopulmonary Exercise Testing in the Age of New Heart Failure Therapies: Still a Powerful Tool?
Bras, P. G., Gonçalves, A. V., Reis, J., Moreira, R. I., Pereira‐da‐Silva, T., Rio, P., Timóteo, A. T., Silva, S., Soares, R. M., & Ferreira, R. C. (2023) · Biomedicines · doi:10.3390/biomedicines11082208 · Cited by 4
“These findings suggest that new variables may be necessary for risk stratification and patient selection for advanced HF therapies in a contemporary HFrEF population, which presents a challenge due to the increasingly wide variety of HF therapies, which are rapidly evolving, such as with the introduction of guanylate…”
BackgroundZhang, C., Hou, T., Liang, W.-R., Hao, C., Wang, F., Xin, J.-Y., Su, B., Ning, M., & Liu, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23353 · Cited by 2
New Drug: Vericiguat for chronic heart failure
(2023) · Australian Prescriber · doi:10.18773/austprescr.2023.031 · Cited by 2
Sex differences in pharmacotherapy for heart failure
Cho, I. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e3 · Cited by 2
“In randomized controlled clinical trials investigating ivabradine [57] and vericiguat [58], researchers observed no significant sex-related differences in the drugs’ efficacy or safety profiles among patients with HFrEF.”
BackgroundChen, P., Wang, Y., Liu, X., Yu, J., & Zheng, X. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00637-5 · Cited by 2
“%) in both control and vericiguat groups were both derived from the VICTORIA study [7].”
InfluentialThe role of phosphodiesterase 9A inhibitors in heart failure
Foroshani, S., Karp, A., Aronow, W. S., & Lanier, G. M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2349813 · Cited by 2
Asano, T., Maeno, Y., Nakano, M., Taguri, M., Miyasaka, M., Nakai, D., Miyazaki, I., Nasu, T., Tanimoto, S., Masuda, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102775 · Cited by 2
“…sodium–glucose cotransporter 2 inhibitors (SGLT2is), hyperpolarization-activated cyclic nucleotide-gated channel (HCN) blockers, soluble guanylate cyclase (sGC) stimulators, and selective cardiac myosin activators, have been reported to provide additive benefits to conventional HF drugs [4–8].”
BackgroundMolecular Mechanisms of the Failing Heart: A Fatal Regression?
Katoh, M., Komuro, J., Inoue, S., Nakayama, Y., & Komuro, I. (2024) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2024.07 · Cited by 2
Voronkov, L. G., Долженко, М. М., Zharinov, O. J., Zaichenko, H. V., Ivanov, D. D., Koval, O., Kravcheniuk, Y. Y., Лашкул, Д. А., Parkhomenko, A. N., Різниченко, А., et al. (2024) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2024.3.5057 · Cited by 4
Heart Failure Drug Development Over the Eras
Blumer, V. L., Januzzi, J. L., Lindenfeld, J., Solomon, S. D., Psotka, M. A., Carson, P. E., Bristow, M. R., Abraham, W. T., Gandotra, C., Saville, B. R., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.03.021 · Cited by 2
Self-citationHow to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure
Newman, E., Kamanu, C., Gibson, G. T., & Brailovsky, Y. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02101-x · Cited by 4
“Patients on long-acting nitrates, PDE-5 inhibitors, IV inotropes, and LVADs were excluded from the trial [32].”
BackgroundLeft Ventricular Failure: Pathophysiology, Diagnosis, Treatment, and Future Directions
Bhandari, S., Verma, V. D., & Goyal, A. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24sep1247 · Cited by 2
Indian Experience with Vericiguat: A Review Based upon Case Series
Kaul, U., Dalal, J. J., Hiremath, J., Seth, S., Mehta, A., Juvale, N., & Jariwala, P. V. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0696 · Cited by 2
“15 Although long-term follow-up data is currently lacking, discussing early vericiguat initiation in different WHF patient profiles will help clinicians better manage WHF patients in their clinical settings.”
Vesikansa, A., Mehtälä, J., Smith, S., Kirjavainen, A., Huupponen, J., Säävuori, N., Pitkänen, K., & Ukkonen, H. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2024.0028 · Cited by 2
Zhao, X., Hu, N., Wang, L., & Xia, Z. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2484848 · Cited by 2
“In the phase III VICTORIA clinical trial of patients with HFrEF [8], it has been confirmed that vericiguat could reduce cardiovascular mortality and hospitalisation.”
InfluentialVericiguat Experience in Durable Left Ventricular Assist Device Patients
ELAD, B., Lee, C., Baranowska, J., Lotan, D., Fried, J., Clerkin, K. J., Raikhelkar, J., Valledor, A. F., Moeller, C. M., Sayer, G. T., et al. (2025) · Artificial Organs · doi:10.1111/aor.14971 · Cited by 2
Isath, A. M., & Panza, J. A. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.04.001 · Cited by 3
Ramadan, M. M., Alshawi, A. L., Mostafa, Y. A., Al-Obeid, M. T., & Elmahal, M. (2025) · Cureus · doi:10.7759/cureus.82128 · Cited by 6
Yoon, M., Park, J. J., Youn, J., Lee, S. E., Lee, H., Choi, J., Kim, K. H., Yang, D. H., Cho, M., Kang, S., et al. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0007 · Cited by 2
Heart Failure with Reduced Ejection Fraction
Barkoudah, E., & Yancy, C. W. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.010 · Cited by 2
Vericiguat, a Soluble Guanylate Cyclase Stimulator Approved for Heart Failure Treatment
Kallash, M., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000963 · Cited by 3
Huang, W., Tang, H., Li, Y., Chen, W., Chang, S., Bian, J., Ahmed, M. M., Kimmel, S. E., & Guo, J. S. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00745-w · Cited by 3
Geographic Variation and Human Development Index in Heart Failure With Reduced Ejection Fraction
Solal, A. C., Alemayehu, W. G., Lam, C. S. P., Tsutsui, H., Zhang, J., Godoy-Palomino, A., Tziakas, D. N., Corda, S., McMullan, C. J., Ezekowitz, J. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102548 · Cited by 2
Self-citationLópez-Guillén, J. L., Esmel-Vilomara, R., Rodoman, I., Constante, A. D., Kendall, I. S., Freixa‐Benavente, A., Diaz‐Gil, D., Cantarutti, N., Moscatelli, S., & Jeewa, A. (2025) · European Journal of Pediatrics · doi:10.1007/s00431-025-06263-w · Cited by 2
“…HF therapies include omecamtiv mecarbil , a cardiac myosin activator that enhances systolic function by improving myosin-actin interactions [113], and vericiguat , a soluble guanylate cyclase stimulator that enhances nitric oxide signaling, promoting vasodilation and improved hemodynamics [114].”
Polypill in heart failure: a pathway to simplified treatment and improved adherence and outcomes
Keramida, K., Savarese, G., Filippatos, G. S., & Yusuf, S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10559-2 · Cited by 2
Assessing the lifetime benefit of heart failure therapies
Psotka, M. A., & Teerlink, J. R. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30929-6 · Cited by 2
Novel Non-pharmaceutical Advancements in Heart Failure Management: The Emerging Role of Technology
Nolan, M. T., Tan, N., & Neil, C. (2021) · Current Cardiology Reviews · doi:10.2174/1573403x17666210831144141 · Cited by 2
Habon, T., & Sepp, R. (2022) · Cardiologia Hungarica · doi:10.26430/chungarica.2022.52.2.122 · Cited by 2
NEW GDMT OF HEART FAILURE WITH REDUCED EJECTION FRACTION (HFrEF): THE ROLE OF DAPAGLIFLOZIN
Sukandi, E., Farianty, A., & Maulana, E. Z. (2022) · Conferences of Medical Sciences Dies Natalis Faculty of Medicine Universitas Sriwijaya · doi:10.32539/confmednatalisunsri.v4i1.91 · Cited by 2
Vericiguat – neue Therapieoption für Patienten mit Herzinsuffizienz
Bauersachs, J. K., & Nitschmann, S. (2020) · Der Internist · doi:10.1007/s00108-020-00828-7 · Cited by 2
“Dies spiegelt sich auch in einer hohen Ereignisrate wider, die schon nach weniger als 12 Monaten medianer Behandlungszeit zum Abschluss der ereignisgetriebenen VICTORIA-Studie führte [1].”
BackgroundChronic and End-Stage Heart Failure
Zlotoff, D. A., & Ho, J. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_25 · Cited by 2
Vericiguat, organic nitrates, and heart failure in African Americans
Ilonze, O. J., & Guglin, M. E. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.06.033 · Cited by 2
Borisov, A. A., Gvozdeva, A. D., & Ageev, F. T. (2021) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2021-12-2-6-15 · Cited by 3
Cardiorenal Effects of Long‐Term Phosphodiesterase V Inhibition in Pre–Heart Failure
Hubers, S. A., Wan, S., Adel, F., Benike, S. L., Burnett, J. C., Scott, C., & Chen, H. H. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022126 · Cited by 2
Raschi, E., Diemberger, I., Sabatino, M., Poluzzi, E., Ponti, F. D., & Potena, L. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2027909 · Cited by 2
Majoros, Z., Kiss, R. G., & Pál, T. (2022) · Cardiologia Hungarica · doi:10.26430/chungarica.2022.52.2.112 · Cited by 3
Kalyuzhin, V. V., Teplyakov, A. T., Bespalova, I. D., Kalyuzhinа, E. V., Terentyeva, N. N., Grakova, E. V., Kopeva, K. V., Usov, V. Y., Garganeeva, N. P., Павленко, О. А., et al. (2022) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2022-3-181-197 · Cited by 4
Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
Mihalek, A. D., Scott, C. D., & Mazimba, S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s383572 · Cited by 6
“Its use in patients with progressive HFrEF despite background therapy showed benefit in reducing death and hospitalization despite increased rates of anemia.(47) These results are provocative and lay the groundwork for conversations and investigations into the use of the sGC stimulators to treat heart failure patients.”
ResultEffects of Low-Dose Tadalafil in a Patient with Biventricular Heart Failure: A Case Report
Kono, S., Takahashi, J., Shimozono, K., Kumanomido, J., Inoguchi, N., Nohara, S., Itaya, N., Nakayoshi, T., & Fukumoto, Y. (2023) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2023.j020 · Cited by 2
Boytsov, S. A., Tereshchenko, S. N., Вадимовна, В. С., Galyavich, A. S., Анатольевна, Г. А., Глезер, М. Г., Duplyakov, D. V., Жиров, И. В., Kobalava, Z. D., Lopatin, Y. M., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5423 · Cited by 2
Muminovic, A., Chirkov, Y. Y., & Horowitz, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119273 · Cited by 2
“Indeed, the sGC stimulator vericiguat has recently been reported to be effective in the clinical context of heart failure, reducing the rise of the combination of cardiovascular death and hospital admission for heart failure with no significant increase in associated major bleeding risk [32].”
BackgroundSperanza-Sánchez, M., Zavaleta‐Monestel, E., Sancho-Zumbado, S., Arguedas‐Chacón, S., & Quirós-Romero, A. (2023) · Cureus · doi:10.7759/cureus.39570 · Cited by 2
“Current guidelines for managing heart failure with reduced ejection fraction (HFrEF) recommend a foundational quadruple therapy that includes beta blockers, sodium-glucose cotransporter-2 (SGLT2) inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and mineralocorticoid receptor antagonists (MRAs) [3].”
BackgroundMethodInfluentialMétodos diagnósticos cardiovasculares en pacientes con diabetes mellitus. Revisión
Ramón-Ríos, A., Espejel-Guzman, A., Cabello‐Ganem, A., Serrano‐Roman, J., Aparicio-Ortiz, A. D., Fernández-Badillo, V., Palacios-Cruz, M., & Espinola-Zavaleta, N. G. (2023) · Gaceta Médica de México · doi:10.24875/gmm.m23000766 · Cited by 3
Lu, L., Tan, P., Li, G., Yang, S., Meng, G., & Zhang, C. (2023) · Medicine · doi:10.1097/md.0000000000036530 · Cited by 2
Rao, J., Chen, X., Liu, Y., Wang, X., Cheng, P., & Wang, Z.-N. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2382226 · Cited by 2
“While verici-guat proves effective in treating HF treatment and lowering cardiovascular mortality and hospitalization rates in HF patients, the occurrence of adverse events deserves attention [12].”
Lou, J., Li, N., Jiang, X., Cai, X., Wang, L., Wu, X., Zhang, W., Jin, C., & Zhuang, X. (2024) · Pharmaceuticals · doi:10.3390/ph17091140 · Cited by 2
“…therapy can significantly reduce the risk of cardiovascular death or hospitalization for heart failure in patients, providing a new approach to the treatment of heart failure [10,11]. been noted in previous studies to potentially affect the pharmacokinetics of numerous drugs when co-administered.”
BackgroundTópicos Emergentes em Insuficiência Cardíaca: Nova Era do Tratamento Farmacológico
Marcondes‐Braga, F. G., Ramires, F. J. A., Figueiredo, E. L., Figueiredo, J. A., Neto, L. B. D. S., & Rassi, S. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201106 · Cited by 2
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.